Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide maintenance after commercial anti-CD19 CAR T-cell therapy in high-risk relapsed/refractory aggressive large B-cell lymphoma
2023-506705-20-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golcadomide in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma, transformed (t-FL) and 2 more, sponsored by LYSARC. Primary endpoint: Complete metabolic response rate at 3 months. Planned start Jun 2024; status: authorised.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)transformed marginal zone lymphoma (tMZL)large-cell lymphoma
Beyond the preview
Go deeper on 2023-506705-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506705-20-00.